Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
Launched by HÔPITAL EDOUARD HERRIOT · Apr 11, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of three different methods for screening colorectal cancer: colonoscopy, colon capsule, and a fecal immunological test. It specifically focuses on first-degree relatives (like parents, siblings, or children) of people who have had colorectal cancer. The goal is to find out which screening method works best for detecting early signs of cancer in people aged 45 and older who have not been screened before.
To participate in this study, individuals need to be at least 45 years old, have a family history of colorectal cancer, and must not have undergone any previous screening for colorectal cancer. Participants will receive one of the three screening tests and will be monitored during the trial. It’s important to know that those with a known genetic predisposition to colorectal cancer or other serious health issues are not eligible to participate. This study is currently recruiting participants, and it’s a great opportunity to contribute to research that could improve cancer screening methods for families at risk.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • History of colorectal cancers (any age) in first-degree relatives (parents, children, siblings including half-brothers and sisters)
- • Age \> or = 45 years
- • No previous colorectal cancer screening
- • Informed patient
- • Patient having signed the consent form
- • Patient affiliated to a social security system or recipient of such system
- Exclusion criteria:
- * Any previous colorectal cancer screening:
- • History of blood tests in the stool (hemoccult, fecal immunological test, ...)
- • History of colonic capsule screening
- • History of colonoscopy
- • Any known advanced neoplasia or colorectal cancer
- • Known genetic predisposition to colorectal cancer (very high risk group)
- • Adults protected by law (under guardianship or trusteeship)
- • Other metastatic cancers
- • Life-threatening diseases
About Hôpital Edouard Herriot
Hôpital Édouard Herriot, a leading healthcare institution in Lyon, France, is dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its multidisciplinary approach and state-of-the-art facilities, the hospital collaborates with a diverse team of healthcare professionals and researchers to conduct rigorous studies across various therapeutic areas. Committed to ethical standards and patient safety, Hôpital Édouard Herriot aims to contribute significantly to the development of new therapies and enhance the understanding of complex health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Avignon, , France
Toulouse, , France
Marseille, , France
Toulouse, Midi Pyrénées, France
Colmar, Alsace, France
Pessac, Aquitaine, France
Dijon, Bourgogne, France
Brest, Bretagne, France
Rennes, Bretagne, France
Besançon, Franche Comté, France
Bobigny, Ile De France, France
Créteil, Ile De France, France
Paris, Ile De France, France
Paris, Ile De France, France
Limoges, Limousin, France
Rouen, Normandie, France
Nantes, Pays De La Loire, France
Nice, Provence Alpes Côte D'azure, France
Avignon, Provence Alpes Côte D'azur, France
Marseille, Provence Alpes Côte D'azur, France
Lyon, Rhône Alpes, France
Saint Priest En Jarez, Rhône Alpes, France
Saint Priest En Jarez, , France
Besançon, , France
Nice, , France
Lyon, , France
Patients applied
Trial Officials
Jean-Christophe Saurin, Pr
Principal Investigator
Hôpital Edouard Herriot - Hospices civils de Lyon
Robert Benamouzig, Pr
Study Chair
Hôpital Avicenne - Assistance publique-Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials